Oncotelic Therapeutics, Inc.
OTLC
Rank in Stocks
#29377
Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage... Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 β an antisense compound designed to inhibit TGF-Γ2 β is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses. The company's pipeline further includes OXi4503, which is being advanced for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and CA4P, intended for the treatment of advanced metastatic melanoma.
Share Price
$0.0173
Last synced: 2026-11-09
Market Cap
$7.91M
Change (1 day)
73.00%
Change (1 year)
-79.74%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Oncotelic Therapeutics, Inc. (OTLC)
Category
Healthcare
EPS for Oncotelic Therapeutics, Inc. (OTLC)
EPS as of June 2026 TTM: $0.59
According to Oncotelic Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $0.59. At the end of 2025 the company had an EPS of $0.59, an increase over its 2024 EPS of $-0.01.
EPS history for Oncotelic Therapeutics, Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.59 | 0.00% |
| 2025 | $0.59 | -5,367.86% |
| 2024 | $-0.01 | -44.00% |
| 2023 | $-0.02 | -143.10% |
| 2022 | $0.05 | -223.40% |
| 2021 | $-0.04 | -71.08% |
| 2020 | $-0.13 | 8.33% |
| 2019 | $-0.12 | 63.27% |
| 2018 | $-0.07 | -85.87% |
| 2017 | $-0.52 | 1.96% |
| 2016 | $-0.51 | -5.56% |
| 2015 | $-0.54 | -28.00% |
| 2014 | $-0.75 | -74.58% |
| 2013 | $-2.95 | -46.17% |
| 2012 | $-5.48 | -47.16% |
| 2011 | $-10.37 | -85.52% |
| 2010 | $-71.60 | -35.56% |
| 2009 | $-111.11 | -33.69% |
| 2008 | $-167.56 | -4.36% |
| 2007 | $-175.20 | 30.47% |
| 2006 | $-134.28 | -7.62% |
| 2005 | $-145.35 | 0.05% |
| 2004 | $-145.28 | -4.63% |
| 2003 | $-152.33 | -27.88% |
| 2002 | $-211.22 | 139.91% |
| 2001 | $-88.04 | -54.87% |
| 2000 | $-195.06 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | 2,554.24% |
US
|
|
| $-7.07 | -1,298.31% |
US
|
|
| $-5.29 | -996.61% |
AU
|
|
| $12.88 | 2,083.07% |
BE
|
|
| $21.56 | 3,554.24% |
NL
|
Questions about Oncotelic Therapeutics, Inc.'s earnings per share (EPS)
What is Oncotelic Therapeutics, Inc.'s earnings per share (EPS)?
Oncotelic Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $0.59, as of Jun 2026.
What was Oncotelic Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Oncotelic Therapeutics, Inc.'s earnings per share (EPS) was $0.59, compared with $-0.01 in 2024.
How has Oncotelic Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Oncotelic Therapeutics, Inc.'s earnings per share (EPS) was highest in 2025 ($0.59) and lowest in 2020 ($-0.13).
How does Oncotelic Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Oncotelic Therapeutics, Inc.'s earnings per share (EPS) ($0.59) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.